SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 2,717.55 |
| Enterprise Value ($M) | 1,806.55 |
| Book Value ($M) | 892.93 |
| Book Value / Share | 13.79 |
| Price / Book | 3.04 |
| NCAV ($M) | 769.09 |
| NCAV / Share | 11.88 |
| Price / NCAV | 3.53 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.17 |
| Return on Assets (ROA) | -0.30 |
| Return on Equity (ROE) | -0.42 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 13.69 |
| Current Ratio | 13.69 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 911.00 |
| Assets | 1,034.84 |
| Liabilities | 141.91 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Avoro Capital Advisors LLC | 9.99 | 105.30 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 10.30 | 10.77 | |
| 13G/A | Atlas Venture Fund X, L.P. | 6.40 | -16.00 | |
| 13G | Fmr Llc | 7.93 | 117.64 | |
| 13G/A | Wellington Management Group Llp | 7.17 | -4.10 | |
| 13D/A | Baker Bros. Advisors Lp | 9.30 | 0.06 | |
| 13G/A | Vanguard Group Inc | 6.73 | 9.21 | |
| 13G/A | BlackRock, Inc. | 6.40 | 6.95 | |
| 13G/A | State Street Corp | 3.41 | -33.45 | |
| 13D/A | Biotechnology Value Fund L P | 9.99 | 24.26 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 121,158 | 311,766 | 38.86 | |
| 241,546 | 716,282 | 33.72 | |
| 81,741 | 337,760 | 24.20 | |
| 50,780 | 227,832 | 22.29 | |
| 56,140 | 228,701 | 24.55 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KLTO – Klotho Neurosciences, Inc. | KOD – Kodiak Sciences Inc. |
| KROS – Keros Therapeutics, Inc. | LBPH – Longboard Pharmaceuticals, Inc. |
| LGND – Ligand Pharmaceuticals Incorporated |
Financial data and stock pages provided by
Fintel.io